fingolimod mylan
mylan ireland limited - fingolimod hydrochlorid - roztroušená skleróza, relaps-remitentní - imunosupresiva - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 a 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
lextemy
mylan ire healthcare limited - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastická činidla - treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix.
dimethyl fumarate neuraxpharm
laboratorios lesvi s.l. - dimethyl fumarát - roztroušená skleróza, relaps-remitentní - imunosupresiva - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.
celdoxome pegylated liposomal
yes pharmaceutical development services gmbh - hydrochlorid doxorubicinu - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastická činidla - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).
afonilum sr 125mg tvrdá tobolka s prodlouženým uvolňováním
viatris healthcare limited, dublin array - 4992 theofylin - tvrdá tobolka s prodlouženým uvolňováním - 125mg - theofylin
afonilum sr 250mg tvrdá tobolka s prodlouženým uvolňováním
viatris healthcare limited, dublin array - 4992 theofylin - tvrdá tobolka s prodlouženým uvolňováním - 250mg - theofylin
bonaxon 0,5mg tvrdá tobolka
egis pharmaceuticals plc, budapešť array - 19410 fingolimod-hydrochlorid - tvrdá tobolka - 0,5mg - fingolimod
capecitabine glenmark 150mg potahovaná tableta
glenmark pharmaceuticals s.r.o., praha array - 14083 kapecitabin - potahovaná tableta - 150mg - kapecitabin
capecitabine glenmark 500mg potahovaná tableta
glenmark pharmaceuticals s.r.o., praha array - 14083 kapecitabin - potahovaná tableta - 500mg - kapecitabin
capecitabine pharmagen 150mg potahovaná tableta
pharmagen cz s.r.o., praha array - 14083 kapecitabin - potahovaná tableta - 150mg - kapecitabin